

Brain and Spine Tumor Board

Provided by Rutgers New Jersey Medical School, Department of Neurosurgery

WebEx Meeting

Wednesday, September 24, 2025, 12:00 – 1:00 PM

Pankaj K Agarwalla, MD; Ada Baisre DeLeon, MD
Esther Nimchinsky, MD, PhD; Vincent Yeung, MD

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Review novel therapies for brain and spine tumors.
- Recognize the importance of multi-disciplinary care of brain and spine tumor patients.
- Coordinate brain and spine tumor patients for clinical trial evaluation.

Target Audience

This activity is designed for neurosurgeons, radiation oncologists, medical oncologists, neuro-radiologists, neuro-pathologists), nurses, and clinical research staff.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Pankaj K. Agarwalla, MD, Ada Baisre DeLeon, MD, Esther Nimchinsky, MD, PhD, and Vincent Yeung, MD, have no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee:

Content Reviewers: Pankaj K. Agarwalla, MD (Activity Director), Ada Baisre DeLeon, MD, Esther Nimchinsky, MD, PhD, and Vincent Yeung, MD, have no relevant financial relationships with ineligible companies to disclose.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth have no relevant financial relationships with ineligible companies to disclose.